CN1029857C - Bacterial strain and its utilization - Google Patents
Bacterial strain and its utilization Download PDFInfo
- Publication number
- CN1029857C CN1029857C CN 90102847 CN90102847A CN1029857C CN 1029857 C CN1029857 C CN 1029857C CN 90102847 CN90102847 CN 90102847 CN 90102847 A CN90102847 A CN 90102847A CN 1029857 C CN1029857 C CN 1029857C
- Authority
- CN
- China
- Prior art keywords
- bacterial strain
- bacterioide
- fragilis
- active bacteria
- bacteria formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a multifunctional No. 1 huaxing (BF839) strain separated from a well-developed baby or the intestinal flora of a young animal by screening. A viable bacterium preparation is prepared through a fermentation technology, can increase the growth and the development of children and have very good therapeutic effect on the prevention and the treatment of chronic enteritis, flora imbalance, upper respiratory tract infection, neurosis, etc., and particularly, the therapeutic effect on paediatric diarrhea and malnutrition is obvious. The multifunctional No. 1 huaxing (BF839) strain is used as a feed additive and can also be used for preparing cosmetics, health foods, beverages, etc., the body weight of fowls and animals and the yield of eggs can be increased, and disease resistance is enhanced.
Description
The invention belongs to technical field of bioengineering, particularly relate to a kind of bacteroides fragilis bacterial strain and application thereof that utilizes microbial fermentation technology to cultivate.
In recent years, American-European advanced country is engaged in the scholar of pathogeny microorganism, many people turn to the research to useful normal microorganism, adopt biotechnology to solve the problem that aspects such as agricultural, livestock industry, body-care, disease preventing and treating (comprise and capture the obstinate fort of cancer) and prolongs life exist.Through international online retrieval, the antitumor action document (F55092322,1978) that relates to bifidus bacillus is arranged, but do not see the report of this class strains separation of relevant bacteroides fragilis, cultivation and application.
The microecosystem of human body and immunity, metabolism, nutrition are relevant, decline along with this system of increase at age is residual gradually and wear out.So the people more than 60 years old is weak and easy cancer stricken easily, then deny less than 60 years old healthy and strong people.Purpose of the present invention is intended to isolate the probiotics that some plays an important role the microecosystem normal physiological bacterium in the low age human or animal body, be transplanted in the human or animal body at advanced age, make its recovery and set up the higher new microecosystem of biomass, improve definite value durability factor level, reach and recover or part is recovered the states such as nutrition, metabolism and immunity that low age is had period.
The present invention implements by following step: screen, isolate multi-functional bacteroides fragilis bacterial strain from well-developed baby or low-aged animal intestinal microflora, utilize microbial fermentation technology to make active bacteria formulation, be used to cure multiple disease, preparation protective foods, beverage, fodder additives and makeup etc.
Bacteroides fragilis is one of normal physiological anaerobic bacterium of human body.This bacterial strain has sent China Committee for Culture Collection of Microorganisms's common micro-organisms center preservation, preserving number CGMCCN0.0157 May 3 nineteen ninety.Identify that through Institute of Microorganism, Academia Sinica and Epidemiology Organic Inst., China Preventive Medical Academy all tentative is bacteroides fragilis (Bacteroides, the Fragilis) bacterial strain in, called after BF839.Because of limit by domestic equipment and condition, still can not make satisfactory conclusion to ultrastructure and some characteristic thereof of BF839 bacterial strain.China Committee for Culture Collection of Microorganisms's medical science bacterium center suggestion " after calibrating, considers to enroll the national standard Cordycepps ".
Through nearly 10 years studies show that, this bacterium has following function: (1) improves body immunity, increases the immune t-cell activity; (2) help the absorption of human body digest food; (3) some toxicant in the degraded intestines; (4) get rid of alien bacteria and settle down, adjust intestinal flora and distribute at enteron aisle; (5) synthetic multivitamin and protein in enteric cavity; (6) anticancer growth etc.
By hundreds of routine clinical verifications, the BF839 preparation can increase upgrowth and development of children, and control acute chronic enteritis, flora imbalance, upper respiratory tract infection and neurosis etc. are all had better curative effect, and is particularly remarkable to infantile diarrhea, malnutritive curative effect especially.Can increase poultry, the weight of animals, egg productivity and strengthen disease resistance as fodder additives, also can be used for preparing makeup, protective foods and beverage etc.
BF839 gets from well-developed baby intestinal flora, puts in the anaerobically fermenting substratum of autogamy fermentation and makes active bacteria formulation.Anaerobically fermenting substratum composition is as follows:
Peptone 0.5-2.5%, glucose 0.2-0.5%, halfcystine 0.001-0.5%, NaCl10.2-0.5%, Na
2HPO
40.1-0.3%, sodium thioglycollate 0.02-0.1%, beef liver or pork liver immersion liquid 30-60%, beef infusion broth 30-60%, yeast extract paste 0.1-0.8%(weight percent).Said BF839 strain culturing temperature is to approach the scope of Mammals body temperature, and optimum temps is 37 ℃, constant temperature 32-40 ℃ through 12-72 hour fermentation culture, 3500 rev/mins centrifugal removes supernatant liquor, survey bacterium uses.
The embodiment of the invention is as follows:
Embodiment one: the BF839 inoculation in 10 liter anaerobically fermenting substratum, was cultivated 24 hours for 37 ℃, and recording every milliliter of viable count is 2084 * 10
6=10
8.2(press log10
n/ ml calculates) 3000-4000 rev/min centrifugal supernatant liquor, washing, the diluted for use of going.
Embodiment two: the BF839 inoculation in 10 liter anaerobically fermenting substratum, was cultivated 24 hours for 37 ℃, and recording every milliliter of viable count is 588 * 10
8=10
9.8(press log10
n/ ml calculates) 3000-4000 rev/min centrifugal supernatant liquor, washing, the diluted for use of going.
Embodiment three: the BF839 inoculation in 10 liter anaerobically fermenting substratum, was cultivated 30 hours for 37 ℃, and recording every milliliter of viable count is 1132 * 10
7=10
9.1(press log10
n/ ml calculates).3000-4000 rev/min of centrifugal supernatant liquor, washing, the diluted for use of going.
Embodiment four: BF839 active bacteria formulation 10ml(viable count 4,000,000,000/ml) of early 10 minutes after the meal clothes next day of boarding at the nursery children for the 3-6 of kindergarten year, observed altogether 11.5 months, the result shows and takes height and the body weight (table 1 that the BF839 active bacteria formulation has significantly increased children, table 2), (table 1, table 2 are seen the literary composition back)
Embodiment five: the BF839 active bacteria formulation is used to improve immunization programs for children power, give the BF839 active bacteria formulation 10ml(viable count 4,000,000,000/ml) of children's day early 10 minutes after the meal clothes of boarding at the nursery in the 3-6 of kindergarten year, employing esterase staining mensuration after 11 months, result show takes the immunologic function (table 3) that the BF839 active bacteria formulation has significantly increased children.(table 3 is seen the literary composition back)
Embodiment six: the BF839 active bacteria formulation is used for the treatment of enteritis, bowel dysfunction, indigestion.236 patients such as acute enteritis, cureless chronic intestinal inflammations (part is made a definite diagnosis through enteroscopy), bowel dysfunction, general liver property and the senile maldigestion that the standard routinely of giving is made a definite diagnosis, infantile diarrhea, amebic dysentery, depressive psychosis, bacillary dysentery, constipation early service once the BF839 active bacteria formulation every day after meal, each 20ml(viable count 4,000,000,000/ml), the efficient 98.3%(table 5 that reaches).(table 4 is seen the literary composition back)
Embodiment seven: the BF839 active bacteria formulation is used to prevent and treat upper respiratory tract infection.BF839 active bacteria formulation 10ml(viable count 2,000,000,000/ml) of early 10 minutes after the meal clothes was observed 11.5 months altogether next day of boarding at the nursery children for the 3-6 of kindergarten year, and the result shows the effect (table 5) that prevention child upper respiratory disease is arranged.(table 5 is seen the literary composition back)
Embodiment eight: with 120 of the poulty house laying hens with age in days of the same race, under identical living condition, use forage feed of the same race, stochastic sampling is divided into each 60 of test group and control groups.Test group is taken bacterium several 2,000,000,000 every day by every chicken amount is admixed in the feed feeding with BF839 viable bacteria additive and is suffered all.31 days trial periods, continued to observe 21 days behind hello the additive with stopping.In amounting to 52 days, 60 egg productivitys of test group increase 17.53Kg(table 6)
Body weight change result behind the table 1 children taking BF839
Continue Time of Administration (moon) n1(test group) the n2(control group) T value P value
2 64 54 2.5 ＜0.05
5 53 46 2.97 ＜0.01
7.5 59 56 3.58 ＜0.01
Height result of variations behind the table 2 children taking BF839
Continue Time of Administration (moon) n1(test group) the n2(control group) T value P value
6 53 46 1.78 ＞0.05
11.5 44 46 2.90 ＜0.01
Table 3 T raji cell assay Raji result
The n1(test group) T value P value n2(control group)
Group experiment 45 38 4.18＜0.01
Pair test 30 30 3.25＜0.01
Table 4 is taken the curative effect of BF839 to intestinal tract disease
The example number each one take bottle number rehabilitation take a turn for the better invalid
Chronic intestinal inflammations 81 1-10 74 61
Acute enteritis 17 1-3 17
Bowel dysfunction 22 1-6 16 42
General maldigestion 32 1-4 30 2
Liver property maldigestion 8 4-10 53
Senile maldigestion 6 3-10 6
Infantile diarrhea 58 1-3 58
Amebic dysentery 141
Depressive psychosis 343
Bacillary dysentery 444
Constipation 444
Sum 236 214 18 4
Percentage 100% 90.7% 7.6% 1.7%
Table 5 BF839 is to the prophylactic effect of upper respiratory tract infection of children
Continue Time of Administration (moon) n1(test group) the n2(control group) T value P value
11.5 63 55 3.12 ＜0.01
Table 6 BF839 increases the egg productivity of chicken
The average egg number of the sum (only) of laying eggs (only/day) total amount of laying eggs (Kg) average egg yield (Kg/ days)
Test group 2,379 45.75 143.09 2.7
Control group 2,124 40.85 125.56 2.42
Claims (2)
1, a kind of bacterioide active bacteria formulation, this bacterioide (depositary institution: China Committee for Culture Collection of Microorganisms common micro-organisms center; Preserving number CGMCCN0.0157; Specific name bacteroides fragilis Bacteroides, Fragilis called after BF839), be to have a strong fermentation character and a FFI bacterial strain in the bacillus fragilis, it is characterized in that the BF839 inoculation in substratum; Peptone 0.5-2.5%, glucose 0.2-0.5%, halfcystine 0.001-0.5%, NaCl0.2-0.5%, Na
2HPO
40.1-0.3%, sodium thioglycollate 0.02-0.1%, beef liver or pork liver immersion liquid 30-60%, beef infusion broth 30-60%, yeast extract paste 0.1-0.8% (weight percent) ferments through 12-72 hour at constant temperature 32-40 ℃, filters, washs, dilutes, surveys bacterium then and use.
2, bacterioide active bacteria formulation according to claim 1 is characterized in that BF839 bacterial strain constant temperature culture temperature is 37 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 90102847 CN1029857C (en) | 1990-05-03 | 1990-05-03 | Bacterial strain and its utilization |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 90102847 CN1029857C (en) | 1990-05-03 | 1990-05-03 | Bacterial strain and its utilization |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1056314A CN1056314A (en) | 1991-11-20 |
| CN1029857C true CN1029857C (en) | 1995-09-27 |
Family
ID=4877730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 90102847 Expired - Fee Related CN1029857C (en) | 1990-05-03 | 1990-05-03 | Bacterial strain and its utilization |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1029857C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103082294A (en) * | 2013-01-21 | 2013-05-08 | 广州知光生物科技有限公司 | Application of bacteroides fragilis in preparation of composition for treating diarrhea |
| CN103146620A (en) * | 2013-03-25 | 2013-06-12 | 广州知光生物科技有限公司 | Bacteroides fragilis with characteristics of probiotics |
| WO2019095508A1 (en) * | 2017-11-17 | 2019-05-23 | 中山大学 | Composition for enhancing immune function of t cells and preparation method therefor |
| CN113151083A (en) * | 2021-04-21 | 2021-07-23 | 中国疾病预防控制中心传染病预防控制所 | Bacteroides dorsalis probiotics and application thereof in preparation of influenza treatment or prevention medicine |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103120705A (en) * | 2013-01-21 | 2013-05-29 | 广州知光生物科技有限公司 | Application of bacteroides fragilis in preparation of composition for treating constipation |
| CN103142658A (en) * | 2013-03-18 | 2013-06-12 | 广州知光生物科技有限公司 | Application of bacteroides fragilis in preparing composition for preventing and treating acute radiation enteritis |
| CN103142656A (en) * | 2013-03-18 | 2013-06-12 | 广州知光生物科技有限公司 | Application of bacteroides fragilis in preparing composition for preventing and treating colon cancer |
| CN103142657A (en) * | 2013-03-18 | 2013-06-12 | 广州知光生物科技有限公司 | Application of bacteroides fragilis in preparing composition for preventing and treating hypercholesteremia |
| CN103156888A (en) * | 2013-03-18 | 2013-06-19 | 广州知光生物科技有限公司 | Application of bacteroides fragilis in preparation of composition for treating inflammatory bowel diseases |
| CN103156887B (en) * | 2013-03-18 | 2015-06-24 | 广州知易生物科技有限公司 | Application of bacteroides fragilis in preparation of composition for promoting bifidobacterium and lactobacillus to grow |
| CN103404707A (en) * | 2013-08-19 | 2013-11-27 | 广州知光生物科技有限公司 | Application of bacteroides fragilis in preparation of compositions for preventing intestinal diseases of animals |
| CN105274019A (en) * | 2014-07-08 | 2016-01-27 | 王军 | Liquid-solid combined fermentation process for Bacteroides fragilis |
| CN105434477B (en) * | 2015-10-29 | 2019-03-05 | 广州普维君健药业有限公司 | Application of the bacteroides fragilis in anti-aquatic pathogenic bacterium |
| CN109528775A (en) * | 2017-09-22 | 2019-03-29 | 中山大学 | Bacteroides fragilis is preparing the application in the drug for treating and preventing tumour |
| CN110025636B (en) * | 2018-01-12 | 2021-07-23 | 石家庄普维生物科技有限公司 | Application of bacteroides fragilis extract in preparation of composition for enhancing immunity |
| CN110283760A (en) * | 2019-07-30 | 2019-09-27 | 集美大学 | A kind of fermentation culture method of common eel source bacteroides fragilis |
| CN112587552B (en) * | 2020-09-17 | 2023-09-12 | 大连图腾生命科学发展有限公司 | Application of bacteroides fragilis839 in preparing medicament for treating or assisting in treating immune related diseases |
-
1990
- 1990-05-03 CN CN 90102847 patent/CN1029857C/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103082294A (en) * | 2013-01-21 | 2013-05-08 | 广州知光生物科技有限公司 | Application of bacteroides fragilis in preparation of composition for treating diarrhea |
| CN103146620A (en) * | 2013-03-25 | 2013-06-12 | 广州知光生物科技有限公司 | Bacteroides fragilis with characteristics of probiotics |
| WO2019095508A1 (en) * | 2017-11-17 | 2019-05-23 | 中山大学 | Composition for enhancing immune function of t cells and preparation method therefor |
| CN113151083A (en) * | 2021-04-21 | 2021-07-23 | 中国疾病预防控制中心传染病预防控制所 | Bacteroides dorsalis probiotics and application thereof in preparation of influenza treatment or prevention medicine |
| CN113151083B (en) * | 2021-04-21 | 2022-05-20 | 中国疾病预防控制中心传染病预防控制所 | Bacteroides dorsalis probiotics and application thereof in preparation of influenza treatment or prevention medicine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1056314A (en) | 1991-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1029857C (en) | Bacterial strain and its utilization | |
| CN102093967B (en) | Mink source enterococcus faecium and application thereof | |
| CN112011481B (en) | Lactobacillus reuteri for preventing and treating bacterial diarrhea of livestock and poultry and application thereof | |
| CN101671638B (en) | New strain of bifidobacterium and fermentative preparation method and application thereof | |
| CN103005159A (en) | Preparation method of ginkgo leaf biological feed additive | |
| CN113907208B (en) | Feed additive for preventing diarrhea of piglets, and preparation method and application thereof | |
| CN1903058A (en) | Ternary active microbiological prepns. for animals and birds | |
| CN110946907A (en) | Traditional Chinese medicine composition for young poultry, liquid fermented traditional Chinese medicine preparation and preparation method thereof | |
| CN104206789A (en) | Feed additive for preventing cow mastitis and brucellosis and preparation method thereof | |
| CN105132321A (en) | Enterococcus faecium, culture medium thereof for high-density solid-state fermentation, and high-density solid-state fermentation method | |
| CN1831114A (en) | Manure enterococcin strain and use thereof | |
| Li et al. | Effects of fermented feed on growth performance, nutrient metabolism and cecal microflora of broilers | |
| CN102907585A (en) | Probiotics and vitamin premix and mixture for middle pig | |
| CN105199978A (en) | Bacillus coagulans preparation for livestock breeding and preparation method thereof | |
| CN113575764B (en) | Saccharomyces cerevisiae culture and application thereof | |
| CN113615766A (en) | Preparation and application of composite plant extract and probiotic biological fermentation feed | |
| KR20160026280A (en) | Non-antibiotics pellet feed for raising animal | |
| CN109874920A (en) | A kind of composite microbial feed additive and preparation method thereof | |
| CN109652334A (en) | A kind of complex microbial inoculum and its preparation method and application | |
| CN101028037A (en) | Feed additive for improving fowl and beast entric immune and its production | |
| CN1322113C (en) | Sporolactobacillaceae and produced preparation of living fungus thereof | |
| CN114052116B (en) | Probiotic plant extract compound biological agent and preparation method and application thereof | |
| CN114908009B (en) | Lactobacillus mucilaginosus PR63 and application thereof | |
| CN1162089C (en) | Microecological regulator for animal and fowl | |
| CN111728081B (en) | Composite bacteria fermentation liquor for feed additive and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |